So … what IS going to be “hot” at ASCO this year?

It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …

Is Gleason pattern 5 resistant to adjuvant androgen deprivation therapy?

In a research study synthesis published in European Urology, Anthony D’Amico raises the hypothesis that androgen deprivation therapy (ADT) is most effective with Gleason pattern 4, but has lesser or no effect when prostate tumors include Gleason pattern 5. … READ MORE …

Active surveillance for men with Gleason 3 + 4 = 7 disease

The “New” Prostate Cancer InfoLink has taken the position for quite a while that active surveillance could well be a highly appropriate management strategy for some men  with a Gleason score of 3 + 4 = 7 at diagnosis (but far from all of them) — if they still met certain other criteria as good candidates for this form of management. … READ MORE …

Is the “flare” response to initiation of LHRH therapy “real” or not?

For all of the past 30 years, it has been the accepted wisdom that starting a patient on medically induced androgen deprivation therapy (ADT, e.g., with leuproplide acetate/Lupron) during treatment of prostate cancer placed the patient at risk for an initial “flare” response that induced a short-term stimulus to serum testosterone levels and therefore to the development of any tumor. … READ MORE …

A long way from actual clinical applicability, but interesting anyway …

There was an intriguing paper in the November 2013 issue of the journal Prostate suggesting that intermittent dosing with testosterone in between doses of androgen deprivation therapies may actually help men in the early stages of castration resistance to respond better to treatment over time. … READ MORE …

OMG … The finger length/prostate cancer risk hypothesis is back again

In July 2010 we commented on an article in The Daily Mail that was based on data from a team of Korean researchers who’d been busily measuring the lengths of the second and fourth fingers of the right hands of men presenting at their urology clinic. They were convinced that there was a correlation between relative finger length and risk for prostate cancer. … READ MORE …

Out on the frontiers of research on the genetics of cancer

For those who like to know what is happening out on the farther reaches of cancer research, there is an interesting article by George Johnson in today’s New York Times. … READ MORE …